MNTA  Momenta Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

1.24B

Vuru Grade

31.00/100

Current Price

$21.96
-0.47 (-2.10%)

Stability Price

$1.35
Overvalued by 93.87%

Company Metrics

  • 13.83 P/E
  • 25.22 P/S
  • 5.82 P/B
  • -1.78 EPS
  • -5.97% Cash ROIC
  • 8.05 Cash Ratio
  • 0 / N/A % Dividend
  • 978,259.00 Avg. Vol.
  • 56.47M Shares
  • 1.24B Market Cap.

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Short Interest Update
OTC Outlook - Jul 28, 2015
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) ensharesed a rise of 8.1% or 565,726 shares in the short positions. The number escalated from 7,018,422 on June 30,2015 to 7,584,148 on July 15,2015.
Stock Insights: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Vanguard Tribune
Momenta Pharmaceuticals Receives Average Recommendation of "Buy" from ... - Watch List News
Why Momenta Pharmaceuticals Inc. Shares Are Surging Higher
Motley Fool - Apr 16, 2015
What: Momenta Pharmaceuticals (NASDAQ:MNTA) shares jumped by more than 10% earlier today following news that the FDA had approved Novartis' (NYSE:NVS) and Momenta's biosimilar to Teva Pharmaceuticals (NYSE:TEVA) Copaxone. So What: ...
Momenta Pharmaceuticals Announces Conference Call Details Regarding FDA ... - GlobeNewswire (press release)
FDA Approves Generic Copaxone, but When Will it Become Available? - Wall Street Journal (blog)
Momenta Pharmaceuticals Inc (NASDAQ:MNTA) in Spotlight
Street Report - Jun 22, 2015
[Globe Newswire] Momenta Pharmaceuticals Inc (NASDAQ:MNTA)(TREND ANALYSIS) announced that Sandoz has initiated its U.S. launch of once daily Glatopa(TM) (glatiramer acetate injection), a generic equivalent of daily COPAXONE(R) 20 mg, ...
Why James Roach Unloaded 25000 Shares of Momenta Pharmaceuticals, Inc. (NASDAQ ... - OctaFinance.com
Analyst Upgrades: Red Hat, Inc., Momenta Pharmaceuticals, Inc., and First ... - Schaeffers Research (blog)
Momenta Pharmaceuticals Inc. (MNTA): New Analyst Report from Zacks Equity ...
Nasdaq - Feb 4, 2015
Cambridge, MA-based Momenta Pharmaceuticals, Inc. is a biotechnology company focused on designing products on the basis of a complex systems analysis platform, analyzing data to assess the biological function of these products and developing ...
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) a Sell: UBS
Market Report - Jul 23, 2015
In a research note issued to investors, span class=”tipranks-expert-name”> Marc Goodman at UBS Downgraded Momenta Pharmaceuticals, Inc. (NASDAQMNTA) to a Sell. The analyst placed a $17.00 price target on the stock which indicates a 22.20% ...
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Brokerage Rating Update - Investor Newswire
Here's Why Momenta Pharmaceuticals, Inc. Shares Took Off Today
Motley Fool - Jun 1, 2015
What's Happening: Shares in Momenta Pharmaceuticals (NASDAQ:MNTA) increased by 10% earlier today on news that the company is presenting updated clinical trial date for its pancreatic cancer therapy at the ASCO conference in Chicago. Why It's ...
Momenta Pharmaceuticals Inc. (MNTA) Has Surged To A New High For The Year - Nasdaq
Analyst Price Target Update on Momenta Pharmaceuticals, Inc.
Money Flow Index - Jul 2, 2015
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA): The mean estimate for the short term price target for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) stands at $21.17 according to 6 Analysts. The higher price target estimate for the stock has been ...
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Analyst Rating Update - American Trade Journal
The Insider, John Bishop Sold 33625 Shares of Momenta Pharmaceuticals, Inc ...
OctaFinance.com - May 13, 2015
The Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) 23.05 +0.16 0.70% 's Senior VP - Pharmaceutical Scie, John Bishop, the insider made a sale of - 33,625 Momenta Pharmaceuticals Inc's shares, estimated based on $20.7 per share. The sold shares a ...
Why Momenta Pharmaceuticals, Inc. Jumped Higher Today
Motley Fool - Feb 19, 2015
What: Momenta Pharmaceuticals (NASDAQ:MNTA) shares surged by more than 10% earlier Thursday, just two days after reporting lower-than-expected fourth-quarter sales and profit.
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results - GlobeNewswire (press release)
Today's Dead Cat Bounce Stock Is Momenta Pharmaceuticals (MNTA)
TheStreet.com - Jul 6, 2015
Compared to other companies in the Biotechnology industry and the overall market, MOMENTA PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Analyst Rating in Focus - Investor Newswire
Why Momenta Pharmaceuticals (MNTA) Could Be a Potential Winner - Zacks.com